| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 49.97 | -1.16 (-2.27%) | 36.73 - 56.68 | 664.3 thousand |
Market data as of 4:00PM 06/19/13. Quotes are delayed by at least 15 min.
| Open | 51.10 |
|---|---|
| Previous Close | 51.13 |
| Day's Range | 49.87 - 51.10 |
| Market Cap | 3.3B |
| Avg Volume (10 Day) | 628.9K |
| Price/Earnings (Trailing 12 Mo.) | 29.6x |
| Earnings Per Share (Trailing 12 Mo.) | 1.73 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Fail |
| Increased shareholder value? | Pass |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Pass |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Research Abstracts, Phase 2 Results, and Market Availability of Formulations and Treatments- Research Report on Teva, Forest, Pharmacyclics, Cubist, and Dr. Reddy's
PR Newswire - Wednesday 06/19/2013 8:00 AM ET
Cubist Names Dr. Lorianne Masuoka Chief Medical Officer
Business Wire - Thursday 06/13/2013 8:30 AM ET
Cubist to Present at Jefferies 2013 Global Healthcare Conference
Business Wire - Thursday 05/23/2013 4:30 PM ET
Cubist Achieves Top Biotech Ranking in Globe 100 List
Business Wire - Sunday 05/19/2013 7:00 AM ET
| CBST | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 17.61% | |
| Net Income Growth (1yr) | 194.62% | |
| Total Debt/Equity | 0.37 | |
| LT Debt/Equity | 0.37 | |
| Earnings Yield | 3.38% | |
| Price/Sales | 3.53 |
| Company | Last | Change |
|---|---|---|
| United Therapeutics Corp | 64.99 | -1.04% |
| Isis Pharmaceuticals Inc | 22.58 | -2.17% |
| Taro Pharmaceutical Industries Ltd | 57.57 | -0.02% |
| Endo Health Solutions Inc | 38.52 | -0.77% |
| The Medicines Co | 33.52 | +3.04% |
Data is delayed by at least 15 min.